 NEWARK, Calif., Dec. 16, 2020 PRNewswire -- Protagonist Therapeutics, Inc. Nasdaq:PTGX today announced that the first subject has been dosed in a Phase 1 study of PN-235 also referenced as JNJ-77242113, an oral interleukin-23 receptor IL-23R antagonist peptide. The study is... 